Galmed Pharmaceuticals (GLMD)
(Delayed Data from NSDQ)
$0.36 USD
+0.01 (1.64%)
Updated Jun 12, 2024 03:26 PM ET
After-Market: $0.34 -0.02 (-5.56%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Galmed Pharmaceuticals Ltd. [GLMD]
Reports for Purchase
Showing records 161 - 180 ( 192 total )
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Weizmann Institute of Science to Evaluate the Effect of Aramchol on Gut Microbiome; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
ARREST Expands Into China; PK Study in Chinese Patients Underway; Affirm Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
1Q16 Review: ARREST Study On Track for Full Enrollment by Year End
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Addressing subset of patient population, while assessing direct effect on fibrosis
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Perspectives on Potential Blockbuster Product Launches in 2016
Provider: Rodman & Renshaw, Co.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Perspectives on Potential Blockbuster Product Launches in 2016
Provider: H.C. Wainwright & Co., Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Cutting the Fat in NASH; Assuming Coverage with a Buy Rating
Provider: H.C. Wainwright & Co., Inc.
Analyst: ARCE E
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
HIV-Associated Lipodystrophy and NAFLD Trial Initiated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
New Indication Provides End Market Diversification; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Key Opinion Leaders on NASH Resolution and Diagnostics; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Potential Competitive Landscape Improvement; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Galmed Pharmaceuticals Ltd.
Industry: Medical - Drugs
U.S. Patient Screening Initiated; 2Q15 Results; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y